FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to hepatology and infectious diseases, and can be used if necessary to determine the average rate of formation of liver fibrosis in patients with chronic hepatitis B (CHB). To do this, the results of transient liver elastometry, the patient’s APRI and Charlson indices, divided by the number of years since the last measurement of these indicators, are evaluated and compared with the calculated values of the average rate of liver fibrosis formation. The calculated values of the average rate of liver fibrosis formation per year are: according to elastometry 1.3 kPa, APRI index 0.5 points, taking into account the influence of concomitant diseases according to the Charlson index 0.3 points. If a patient with CHB has an excess of one or more of the three indicators, the rate of formation of liver fibrosis is considered high and antiviral therapy is carried out. If all the indicators in a patient with CHB are equal to the average rate of formation of liver fibrosis per year, then in this case the rate of formation of liver fibrosis is considered average and antiviral therapy is carried out for 1-2 years. If all the indicators in a patient with CHB are lower than those indicated, then the rate of fibrosis is considered low and antiviral therapy is postponed.
EFFECT: method provides an adequate selection of therapeutic tactics during antiviral therapy and the prevention of adverse outcomes in patients with CHB due to the developed criteria for determining the rate of formation of liver fibrosis per year in patients with CHB, taking into account concomitant pathology.
1 cl, 6 tbl, 4 ex
